Yesterday, Halozyme announced the grant of European Patent No. 4269578, covering the ENHANZE® rHuPH20 product obtained from Halozyme's ENHANZE® manufacturing methods that the Company provides to its current and future licensees. The new patent is licensed under all of Halozyme's ENHANZE® licenses. It will be validated in 37 European countries and expires on March 6, 2029. Halozyme discussed the new European patent and provided an update to its 2024 financial guidance and 5-year financial outlook on a conference call earlier today. To access the webcast and presentation, please visit https://ow.ly/QIQ050Sb7Qt. The press release announcing the patent can be found here: https://ow.ly/s2lW50Sb7Qs
Cogratulations!!! Is it any chance that we collaborate this enzyme in genetically mouse engineer? until now, we have very promising data from Dr Barbacid Mariano´s lab. looking forward to your contact!(psun@cnio.es)
Great news! This has a huge impact on our growth potential. Please check out all our job postings and reach out to me!
Global Business Development Manager @ Devsynthesis India Pvt. Ltd. | Small Molecules | Discovery Chemistry| Process development
2moCongratulations on the grant of the European Patent No. 4269578, Halozyme! This achievement truly reflects the innovative spirit and dedication of the team. Looking forward to seeing the continued success and growth of Halozyme's ENHANZE® rHuPH20 product in the European market.